Patient

Programs

Information For Patients And Families

We aim to address the needs of patients living with cancer with our relentless commitment to safer and more effective treatments.
patient-program-img01
Image of Circles

Cancer Indications Our Programs Support

References
1.
National Institutes of Health. Accessed September 26, 2022. https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq.
2.
American Society of Clinical Oncology Publications. Accessed September 26, 2022. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics.
3.
National Cancer Institute. Accessed January 12, 2023. https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq.
4.
Cancert.Net. Accessed January 12, 2023. https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics.
5.
National Cancer Institute. Accessed January 12, 2023. https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq#:~:text=Myelodysplastic%20syndromes%20are%20a%20group,blood%20cells%20and%20bone%20marrow.
6.
Tricot GJ, Lauer RC, Appelbaum FR, et al.: Management of the myelodysplastic syndromes. Semin Oncol 14 (4): 444-53, 1987.[PUBMED Abstract]
 
 

Hear From Paul, a Patient, on Finding a Cullinan Oncology Clinical Trial

Why patients and clinical trials matter
Cancer is a complex and challenging disease, and we are grateful to every patient who participates in a clinical trial to help advance our collective understanding of cancer and how new medicines work. At Cullinan Oncology, we are committed to creating safer, more effective treatments for patients living with cancer, and without patients participating in clinical trials, we wouldn’t be able to meet that commitment.
 

Harnessing Science for Patient Benefit

Our clinical trials are designed with clinically relevant endpoints and predefined benchmarks for success.